Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Return on Equity (2022 - 2025)

Historic Return on Equity for Prime Medicine (PRME) over the last 4 years, with Q3 2025 value amounting to 1.79%.

  • Prime Medicine's Return on Equity fell 6600.0% to 1.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.79%, marking a year-over-year decrease of 6600.0%. This contributed to the annual value of 1.37% for FY2024, which is 4900.0% down from last year.
  • As of Q3 2025, Prime Medicine's Return on Equity stood at 1.79%, which was down 6600.0% from 2.38% recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Return on Equity peaked at 0.73% during Q2 2022, and registered a low of 2.61% during Q4 2022.
  • Its 4-year average for Return on Equity is 1.02%, with a median of 1.11% in 2024.
  • Over the last 5 years, Prime Medicine's Return on Equity had its largest YoY gain of 14000bps in 2023, and its largest YoY loss of -14900bps in 2023.
  • Over the past 4 years, Prime Medicine's Return on Equity (Quarter) stood at 2.61% in 2022, then soared by 54bps to 1.21% in 2023, then increased by 6bps to 1.14% in 2024, then tumbled by -57bps to 1.79% in 2025.
  • Its Return on Equity stands at 1.79% for Q3 2025, versus 2.38% for Q2 2025 and 1.55% for Q1 2025.